A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2002
11/07/2002	CA2447748A1 Use of hiv-protease inhibitors to block cell migration and/or invasion, tissue infiltration and oedema formation
11/07/2002	CA2446064A1 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
11/07/2002	CA2446052A1 Compositions and methods for treating vulvovaginitis and vaginosis
11/07/2002	CA2446023A1 Cell adhesion and extracellular matrix proteins
11/07/2002	CA2445995A1 Antibacterial agent
11/07/2002	CA2445967A1 Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents
11/07/2002	CA2445871A1 Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors
11/07/2002	CA2445861A1 Pharmaceutically active uridine esters
11/07/2002	CA2445860A1 Pharmaceutical composition including ace/nep inhibitors and bioavailability enhancers
11/07/2002	CA2445839A1 Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
11/07/2002	CA2445826A1 Treatment and diagnosis of macrophage mediated disease
11/07/2002	CA2445819A1 Recombinant expression of hhbv reverse transcriptase (rt)
11/07/2002	CA2445763A1 Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
11/07/2002	CA2445697A1 Drug efflux pump inhibitor
11/07/2002	CA2445568A1 Triazole-derived kinase inhibitors and uses thereof
11/07/2002	CA2445528A1 Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
11/07/2002	CA2445523A1 Composite scaffolds and methods using same for generating complex tissue grafts
11/07/2002	CA2445410A1 Ovary-specific genes and proteins
11/07/2002	CA2445357A1 Pyrazole derived kinase inhibitors
11/07/2002	CA2445338A1 G-protein coupled receptors
11/07/2002	CA2445298A1 Use of agt and its derivatives for manufacturing anti-angiogenesis pharmaceutical compositions
11/07/2002	CA2445262A1 Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
11/07/2002	CA2444436A1 Dual inhibitors of pde 7 and pde 4
11/07/2002	CA2444429A1 Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
11/07/2002	CA2444334A1 Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents
11/07/2002	CA2443835A1 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
11/07/2002	CA2443381A1 Use of azithromycin for the manufacture of a medicament for treatment of non-infective inflammatory diseases
11/07/2002	CA2442608A1 Crystalline hydrochloride salt of (2r)-anti-5-(3-[-4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl)-2-hydroxypoxy}quinoline
11/07/2002	CA2439943A1 Benzimidazoles that are useful in treating sexual dysfunction
11/06/2002	EP1255112A2 Treatment of T-cell mediated diseases
11/06/2002	EP1254668A2 Combination of a serotonin reuptake inhibitor and a GABA-A alpha 2/3 agonist for use in anxiety and depression
11/06/2002	EP1254667A1 Drug comprising combination
11/06/2002	EP1254662A2 Methods and kits for treating depression or preventing deterioration of cognitive function
11/06/2002	EP1254661A1 Method for preventing dyskinesias with selective NMDA-Antagonists
11/06/2002	EP1254660A2 Methods, kits and compositions for using pyrrole derivatives against anxiety
11/06/2002	EP1254270A1 Methods and materials relating to cub domain polypeptides and polynucleotides
11/06/2002	EP1254268A1 Methods and materials relating to leucine-rich repeat protein-like (lrr protein-like) polypeptides and polynucleotides
11/06/2002	EP1254265A1 Methods and materials relating to metallocarboxypeptidase-like polypeptides and polynucleotides
11/06/2002	EP1254260A1 Methods for diagnosing and treating heart disease
11/06/2002	EP1254251A2 Neurosteroids as markers for alzheimer's disease
11/06/2002	EP1254241A2 Phosphatases
11/06/2002	EP1254236A2 Drug metabolizing enzymes
11/06/2002	EP1254235A2 Drug metabolizing enzymes
11/06/2002	EP1254222A1 Human gaba receptor proteins and polynucleotides encoding the same
11/06/2002	EP1254174A2 Human cyr61
11/06/2002	EP1254143A2 Lipid-based drug delivery systems
11/06/2002	EP1254116A1 Alpha v integrin receptor antagonists
11/06/2002	EP1254115A2 Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
11/06/2002	EP1254106A1 Calcilytic compounds
11/06/2002	EP1254102A1 Alkynylsubstituted propionic acid derivatives and their use against diabetes and obesity
11/06/2002	EP1254101A1 Propionic acid derivatives and their use in the treatment of diabetes and obesity
11/06/2002	EP1253947A2 Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
11/06/2002	EP1253945A2 Ace inhibitor-vasopressin antagonist combinations
11/06/2002	EP1253944A2 Pharmaceutical composition comprising a combination of metformin and another antidiabetic agent
11/06/2002	EP1253943A2 Photodynamic therapy for treating conditions of the eye
11/06/2002	EP1253941A1 Pre-transplant accommodated organs resistant to anti-donor immunity
11/06/2002	EP1253939A1 In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent
11/06/2002	EP1253933A2 Method for treating thyroid disorders
11/06/2002	EP1253932A2 Botulinum toxin pharmaceutical compositions
11/06/2002	EP1253931A2 Utilization of protein kinase inhibitor alpha
11/06/2002	EP1253928A2 Novel haptotactic peptides
11/06/2002	EP1253926A1 Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor
11/06/2002	EP1253925A1 Tetrahydropyrimidone inhibitors of fatty acid binding protein and method
11/06/2002	EP1253922A2 Statin-type bone growth stimulators
11/06/2002	EP1253919A1 Method and compositions for treating an inflammatory disease
11/06/2002	EP1253916A1 Method of treating vaginal dryness with nicotinic acetylcholine receptor agonists
11/06/2002	EP1253915A1 Method for treating stress with a precursor of serotonin
11/06/2002	EP1253853A1 Method for classifying and treating physiologic brain imbalances using quantitative eeg
11/06/2002	EP1173207B1 Miotic agents and hypertonic agents containing ophthalmic compositions
11/06/2002	EP1001789B1 Product comprising at least a double stranded rna combined with at least a 6-benzyluracil derivative for a simulatneaous, separated or time-spreaded therapeutic use
11/06/2002	EP0784476B1 Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and optionally a vitamin b 12 compound
11/06/2002	EP0773959B1 Adrenergic receptor
11/06/2002	EP0639970B2 Contraception method using competitive progesterone antagonists and novel compounds useful therein
11/06/2002	CN1378554A Novel fusidic acid derivatives
11/06/2002	CN1378534A Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of coagulation cascade
11/06/2002	CN1378497A Water unstable foam composition
11/06/2002	CN1378472A Synergy between low molecular weight heparin and platelet aggregation inhibitor, providing combination therapy for prevention and treatment of various thromboembolic disorders
11/06/2002	CN1378460A Skin immune function controlling agents
11/06/2002	CN1378459A Treatment of auto immune diseases with antagonists which bind to B cell surface markers
11/06/2002	CN1378457A Methods and compositions useful for modulation of angiogenesis using protein kinase Raf and Ras
11/06/2002	CN1378455A Use of diterpenoid triepoxides as anti-proliferative agent
11/06/2002	CN1378441A Use of conjugated linoleic acid (CLA) for topical treatment of cellulite
11/06/2002	CN1378423A Active ingredient compositions having insecticidal and acaricidal properties
11/06/2002	CN1093760C Use of carbazole compounds for treating congenstive heart failure medicine
11/05/2002	US6476187 Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
11/05/2002	US6476079 Devices for the delivery of drugs having antiprogestinic properties
11/05/2002	US6476078 Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
11/05/2002	US6476063 Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith
11/05/2002	US6476043 Use of camptothecin derivatives, with reduced gastrointestinal toxicity
11/05/2002	US6476042 Combination therapy for the treatment of migraine
11/05/2002	US6476038 Amino substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
11/05/2002	US6476037 L-arginine and phosphodiesterase (PDE) inhibitor synergism
11/05/2002	US6476034 Antiviral azaindole derivatives
11/05/2002	US6476026 Compounds and compositions as protease inhibitors
11/05/2002	US6476018 Fused imidazole derivatives as multidrug resistance modulators
11/05/2002	US6476014 Chelated 8-hydroxyquinoline for the treatment of epithelial lesions
11/05/2002	US6476007 Isoform specific inhibition for treatment of pain and reduction of anesthetic threshold
11/05/2002	US6475996 Use of a vector expressing DNA polymerase β as medicine
11/05/2002	US6475992 Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria
11/05/2002	US6475986 Uses of THANK, a TNF homologue that activates apoptosis

1 ... 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 ... 1151